Patents by Inventor Bernard PAYRASTRE

Bernard PAYRASTRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240423944
    Abstract: The food additive lauryl gallate (LG, E312) is a molecule with antioxidant and hydrophobic properties which has also been shown to exert antibacterial, antiviral and anti-tumoral effects. Here, the inventors show that LG at a low concentration has the ability to spontaneously induce washed human platelet shape change, filopodia emission, granule secretion, phosphatidylserine expression and aggregation. LG was able to activate intracellular signaling pathways including Akt, p38MAP-kinase and calcium response and to trigger activation of the ?IIb?3 integrin. LG also significantly potentiated platelet aggregation induced by low doses of collagen or thrombin receptor agonist peptide. Consistent with this, low doses of LG added to human blood promoted a strong platelet thrombotic response under arterial flow on a collagen matrix. As shown by electron microscopy, at a high concentration, LG induced a dramatic platelet membrane modification associated with calcium influx and a slow platelet aggregation response.
    Type: Application
    Filed: October 12, 2022
    Publication date: December 26, 2024
    Inventors: Basma HADJKACEM, Ali GARGOURI, Marie-Pierre GRATACAP, Jennifer SERIES, Cedric GARCIA, Bernard PAYRASTRE
  • Publication number: 20240425863
    Abstract: Ischemic conditions are a leading cause of death for both men and women, Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemic/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.
    Type: Application
    Filed: April 12, 2024
    Publication date: December 26, 2024
    Inventors: Marie-Pierre GRATACAP, Jean DARCOURT, Bart VANHAESEBROECK, Gaëtan CHICANNE, Bernard PAYRASTRE, Vincent LARRUE, Romain SOLINHAC, Aude JAFFRE, Denis VIVIEN, Typhaine ANQUETIL
  • Patent number: 12123000
    Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: October 22, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, UNIVERSITY COLLEGE LONDON, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, UNIVERSITE DE CAEN NORMANDIE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE CAEN
    Inventors: Marie-Pierre Gratacap, Jean Darcourt, Bart Vanhaesebroeck, Gaëtan Chicanne, Bernard Payrastre, Vincent Larrue, Romain Solinhac, Aude Jaffre, Denis Vivien, Typhaine Anquetil
  • Patent number: 12023420
    Abstract: The present invention relates to a vascular stent, deployed or non-deployed, the surface of which is coated by a film comprising at least one protein, to a process for coating of the surface of a vascular stent with a film comprising at least one protein and to a device for carrying out the process according to the invention.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: July 2, 2024
    Assignees: UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM-INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Christophe Cognard, Olivier Eichwald, Cédric Garcia, Nofel Merbahi, Bernard Payrastre, Pierre Sie, Aurélie Tokarski, Ivan Vukasinovic, Mohammed Yousfi
  • Publication number: 20230287430
    Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood—brain barrier (BBB) after ischemic stroke and reduces inflammation.
    Type: Application
    Filed: November 15, 2022
    Publication date: September 14, 2023
    Inventors: Marie-Pierre GRATACAP, Jean DARCOURT, Bart VANHAESEBROECK, Gaëtan CHICANNE, Bernard PAYRASTRE, Vincent LARRUE, Romain SOLINHAC, Aude JAFFRE, Denis VIVIEN, Typhaine ANQUETIL
  • Publication number: 20210238605
    Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an pot ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For NI instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (UR) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 5, 2021
    Inventors: Marie-Pierre GRATACAP, Jean DARCOURT, Bart VANHAESEBROECK, Gaëtan CHICANNE, Bernard PAYRASTRE, Vincent LARRUE, Romain SOLINHAC, Aude JAFFRE, Denis VIVIEN, Typhaine ANQUETIL
  • Publication number: 20210213178
    Abstract: The present invention relates to a vascular stent, deployed or non-deployed, the surface of which is coated by a film comprising at least one protein, to a process for coating of the surface of a vascular stent with a film comprising at least one protein and to a device for carrying out the process according to the invention.
    Type: Application
    Filed: June 5, 2019
    Publication date: July 15, 2021
    Inventors: Christophe COGNARD, Olivier EICHWALD, Cédric GARCIA, Nofel MERBAHI, Bernard PAYRASTRE, Pierre SIE, Aurélie TOKARSKI, Ivan VUKASINOVIC, Mohammed YOUSFI